It is currently trading at $21.35 marginally over $20.27, the stock’s 50 day moving average and which is slightly above the 200 day moving average of $20.17. The 50 day moving average moved up $1.08 and the 200 day average went up by +5.84%. Luminex Corporation shares had a trading volume of 549K in the last trading session. Trading volume was up 330.64% over the stocks average daily volume.
Short traders are more bullish on shares of the company lately as shown by the decrease in short interest. The firm saw a fall in short interest from September 29, 2017 to October 13, 2017 of -2.10%. Short interest fell 57,585 over that timeframe. The short-interest ratio decreased to 21.0 and the short interest percentage is 0.06% as of October 13.
There has been some selling insider activity on Luminex Corporation (NASDAQ:LMNX) recently. Robert J. Cresci, Director disclosed the sale of 19,631 shares of (LMNX). The shares sold for $19.03. Cresci now owns $4,684,596 of the stock according to the SEC filing.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Thomson Horstmann & Bryant Inc had sold 38,020 shares trimming its holdings by 9.2%. The value in dollars decreased from $8,755,000 to $7,654,000 a change of $1,101,000 since the last quarter. First Trust Advisors LP reduced its position by selling 8,076 shares a decrease of 33.8%. First Trust Advisors LP now holds 15,813 shares valued at $321,000. The total value of its holdings decreased 36.4%.
As of quarter end Nationwide Fund Advisors had disposed of a total of 578 shares trimming its position 1.3%. The value of the investment in (LMNX) went from $909,000 to $863,000 decreasing 5.1% quarter over quarter. As of quarter end Aperio Group, LLC had sold 3,782 shares trimming its stake by 10.6%. The value of the total investment in Luminex Corporation decreased from $752,000 to $647,000 a change of 14.0% quarter to quarter.
The company is up since yesterday’s close of $21.35. Luminex Corporation recently declared a dividend paid on Friday the 14th of July 2017. The dividend was $0.060 per share for the quarter or $0.24 on an annualized basis. This dividend amount represented a yield of $1.18. The ex-dividend date was set for Thursday the 21st of September 2017.
The P/E ratio is currently 66.10 and the market cap of the company is 940.92M. In the latest earnings report the EPS was $0.32 and is projected to be $0.69 for the current year with 44,071,000 shares outstanding. Next quarter’s EPS is forecasted to be $0.19 and the next full year EPS is projected to be $0.72.
Luminex Corporation, launched on June 19, 1998, develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Business’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Business’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories..